EndoDmOnSpot is updated review of Endocrinology and Diabetes for all healthcare providers.Account is managed by Makkah chapter of Saudi Society of Endocrinology
The progression of retinopathy seen in the subcutaneous semaglutide study is likely a consequence of rapid glycemic lowering (similar to that seen in other settings) rather than a direct effect of the drug
For longer-term control of hypercalcemia in patients with more severe (calcium >14 mg/dL) or symptomatic hypercalcemia due to excessive bone resorption, suggest the addition of an IV bisphosphonate
Vitamin D replacement therapy is necessary for children presenting with low concentrations of 25-hydroxyvitamin D (25OHD; ie, <20 ng/mL [50 nmol/L]) or rickets.
Most GLP-1 receptor agonists are initiated at a low dose and then slowly advanced to avoid adverse gastrointestinal side effects, which are relatively common, usually affecting from 15 to 45 percent of patients.
Patients with hypercalcemia of malignancy often have higher concentrations of, and more rapid increases in, serum calcium and consequently are more symptomatic
GLP-1-based therapies are appropriate to use in combination with metformin (and/or another oral agent), particularly in patients with existing ASCVD, when weight loss or avoidance of hypoglycemia is a primary consideration, when (A1C) is well above goal (eg, >8.5 percent)
Hypoparathyroidism occurs when there is destruction of the parathyroid glands (surgical, autoimmune), abnormal parathyroid gland development, altered regulation of parathyroid hormone (PTH) production, or impaired PTH action
In patients with hypoalbuminemia due to chronic illness or malnutrition, there may be an associated reduction in the serum total calcium concentration due to proportionally reduced binding of calcium to albumin
In patients with type 2 diabetes and heart failure and/or kidney disease, all SGLT2 inhibitors have shown salutary effects; choice of agent is primarily dictated by provider preference, insurance formulary restrictions, kidney function, and cost.